The role of interleukin‐36 in health and disease states
Authors:
Open Access
- 23 May 2024
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , 1910-1925
Abstract
The interleukin (IL)‐1 superfamily upregulates immune responses and maintains homeostasis between the innate and adaptive immune systems. Within the IL‐1 superfamily, IL‐36 plays a pivotal role in both innate and adaptive immune responses. Of the four IL‐36 isoforms, three have agonist activity (IL‐36α, IL‐36β, IL‐36γ) and the fourth has antagonist activity (IL‐36 receptor antagonist [IL‐36Ra]). All IL‐36 isoforms bind to the IL‐36 receptor (IL‐36R). Binding of IL‐36α/β/γ to the IL‐36R recruits the IL‐1 receptor accessory protein (IL‐1RAcP) and activates downstream signalling pathways mediated by nuclear transcription factor kappa B and mitogen‐activated protein kinase signalling pathways. Antagonist binding of IL‐36Ra to IL‐36R inhibits recruitment of IL‐1RAcP, blocking downstream signalling pathways. Changes in the balance within the IL‐36 cytokine family can lead to uncontrolled inflammatory responses throughout the body. As such, IL‐36 has been implicated in numerous inflammatory diseases, notably a type of pustular psoriasis called generalized pustular psoriasis (GPP), a chronic, rare, potentially life‐threatening, multisystemic skin disease characterised by recurrent fever and extensive sterile pustules. In GPP, IL‐36 is central to disease pathogenesis, and the prevention of IL‐36‐mediated signalling can improve clinical outcomes. In this review, we summarize the literature describing the biological functions of the IL‐36 pathway. We also consider the evidence for uncontrolled activation of the IL‐36 pathway in a wide range of skin (e.g., plaque psoriasis, pustular psoriasis, hidradenitis suppurativa, acne, Netherton syndrome, atopic dermatitis and pyoderma gangrenosum), lung (e.g., idiopathic pulmonary fibrosis), gut (e.g., intestinal fibrosis, inflammatory bowel disease and Hirschsprung's disease), kidney (e.g., renal tubulointerstitial lesions) and infectious diseases caused by a variety of pathogens (e.g., COVID‐19; Mycobacterium tuberculosis, Pseudomonas aeruginosa, Streptococcus pneumoniae infections), as well as in cancer. We also consider how targeting the IL‐36 signalling pathway could be used in treating inflammatory disease states.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 158 references indexed in Scilit:
- Plasma IL-36α and IL-36γ as Potential Biomarkers in Interstitial Lung Disease Associated with Rheumatoid Arthritis: a Pilot Study in the Chinese PopulationInflammation, 2022
- IL‐36γ and IL‐36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress‐Induced Cell DeathAdvanced Science, 2021
- IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymoreCellular and Molecular Life Sciences, 2021
- Identification of small‐molecule elastase inhibitors as antagonists of IL‐36 cytokine activationFEBS Open Bio, 2018
- Interleukin‐36 receptor mediates the crosstalk between plasma cells and synovial fibroblastsEuropean Journal of Immunology, 2017
- IL-36 cytokines are increased in acne and hidradenitis suppurativaArchives of Dermatological Research, 2017
- Altered expression of IL36γ and IL36 receptor (IL1RL2) in the colon of patients with Hirschsprung’s diseasePediatric Surgery International, 2016
- Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patientsArchives of Dermatological Research, 2015
- Expression of IL‐1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL‐1F8 and IL‐1F9European Journal of Immunology, 2011
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004